Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis.

ABSTRACT:

Background

There is little published evidence on how pack size impacts on health system costs. In the UK, children and adolescents aged 10 to < 18 years with prolonged acute convulsive seizures (PACS) occurring in the community setting are usually managed by the administration of buccal midazolam: Epistatus^® or Buccolam^®. These two preparations have markedly differing cost structures, being sold at different prices and presented as single units versus 4-packs, respectively. Consequently, the cost-per-PACS and overall budget impact of the two products cannot be simply inferred but is instead dependent on the likelihood of use. Also relevant to its likelihood of use is midazolam's status as a controlled substance under the Misuse of Drugs Act.

Objective and m

SUBMITTER: Ludwig C 

PROVIDER: S-EPMC7018870 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature